

Kathleen I Pritchard, Cm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7544095/publications.pdf>

Version: 2024-02-01

221
papers

40,505
citations

5896

81
h-index

2448

197
g-index

225
all docs

225
docs citations

225
times ranked

31234
citing authors

#	ARTICLE	IF	CITATIONS
1	Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. <i>Clinical Cancer Research</i> , 2007, 13, 4429-4434.	7.0	3,807
2	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. <i>Annals of Oncology</i> , 2013, 24, 2206-2223.	1.2	2,805
3	Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 520-529.	27.0	2,474
4	Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. <i>Lancet, The</i> , 2012, 379, 432-444.	13.7	1,753
5	A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 1793-1802.	27.0	1,723
6	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 111-121.	27.0	1,558
7	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	1.2	1,449
8	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology, The</i> , 2010, 11, 55-65.	10.7	1,252
9	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 2005-2014.	27.0	1,146
10	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017, 377, 1836-1846.	27.0	1,052
11	Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1262-1271.	6.3	1,048
12	The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2001, 345, 1719-1726.	27.0	819
13	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Status Report 2004. <i>Journal of Clinical Oncology</i> , 2005, 23, 619-629.	1.6	810
14	Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 42-51.	1.6	798
15	Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. <i>Nature Medicine</i> , 1997, 3, 227-230.	30.7	770
16	Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. <i>Journal of Clinical Oncology</i> , 2007, 25, 2127-2132.	1.6	709
17	Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. <i>Lancet Oncology, The</i> , 2011, 12, 236-244.	10.7	575
18	Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 1641-1649.	1.6	555

#	ARTICLE	IF	CITATIONS
19	Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. <i>New England Journal of Medicine</i> , 2016, 375, 209-219.	27.0	507
20	Risk of Menopause During the First Year After Breast Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 1999, 17, 2365-2365.	1.6	503
21	HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2006, 354, 2103-2111.	27.0	498
22	Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. <i>Journal of Clinical Oncology</i> , 2006, 24, 848-855.	1.6	483
23	Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. <i>Advances in Therapy</i> , 2013, 30, 870-884.	2.9	430
24	Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non-Small-Cell Lung Cancer With Disease-Related Anemia. <i>Journal of Clinical Oncology</i> , 2007, 25, 1027-1032.	1.6	392
25	Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. <i>BMJ: British Medical Journal</i> , 2010, 340, c693-c693.	2.3	358
26	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	27.0	349
27	Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3757-3763.	1.6	305
28	Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17. <i>Journal of Clinical Oncology</i> , 2006, 24, 3629-3635.	1.6	285
29	Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis. <i>Journal of Clinical Oncology</i> , 1999, 17, 120-120.	1.6	278
30	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials. <i>Lancet, The</i> , 2019, 393, 1440-1452.	13.7	260
31	American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. <i>Journal of Clinical Oncology</i> , 2009, 27, 3235-3258.	1.6	254
32	Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. <i>Journal of Clinical Oncology</i> , 2009, 27, 4536-4541.	1.6	246
33	Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. <i>Lancet, The</i> , 2009, 374, 2055-2063.	13.7	237
34	Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women. <i>Journal of Clinical Oncology</i> , 2005, 23, 6931-6940.	1.6	227
35	Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27: A Randomized Controlled Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 1398-1404.	1.6	218
36	Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2008, 8, 501-505.	2.4	214

#	ARTICLE	IF	CITATIONS
37	American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor-Positive Breast Cancer: Status Report 2002. <i>Journal of Clinical Oncology</i> , 2002, 20, 3317-3327.	1.6	213
38	Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 581-587.	6.3	205
39	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 419-426.	1.6	203
40	Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. <i>Journal of Clinical Oncology</i> , 2010, 28, 4674-4682.	1.6	196
41	Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. <i>Journal of Clinical Oncology</i> , 2005, 23, 5166-5170.	1.6	189
42	Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations. <i>Journal of Clinical Oncology</i> , 2012, 30, 164-171.	1.6	180
43	Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. <i>Journal of Clinical Oncology</i> , 2008, 26, 1948-1955.	1.6	176
44	Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 215-220.	2.5	170
45	Cancer Treatment-Induced Bone Loss in Breast and Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 5465-5476.	1.6	164
46	HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 736-744.	1.6	162
47	Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13,864 women in seven randomised trials. <i>Lancet Oncology</i> , The, 2021, 22, 1139-1150.	10.7	147
48	A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 77, 285-293.	2.5	145
49	Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. <i>Oncologist</i> , 2015, 20, 474-482.	3.7	145
50	Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2231-2239.	1.6	141
51	Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. <i>Clinical Cancer Research</i> , 2012, 18, 2402-2412.	7.0	132
52	Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 77-82.	1.6	131
53	Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy. <i>Journal of Clinical Oncology</i> , 2006, 24, 4895-4900.	1.6	130
54	Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. <i>Journal of Clinical Oncology</i> , 2008, 26, 1956-1964.	1.6	130

#	ARTICLE	IF	CITATIONS
55	Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Studyâ€”NCIC CTG MA.5. <i>Journal of Clinical Oncology</i> , 2005, 23, 6002-6008.	1.6	129
56	Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision. <i>Journal of Clinical Oncology</i> , 2004, 22, 4312-4318.	1.6	128
57	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 88-96.	10.7	128
58	Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. <i>Journal of Clinical Oncology</i> , 2007, 25, 2006-2011.	1.6	126
59	Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. <i>Journal of Clinical Oncology</i> , 2003, 21, 1944-1951.	1.6	124
60	Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer. <i>Cancer</i> , 2008, 112, 260-267.	4.1	119
61	Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. <i>Annals of Oncology</i> , 2014, 25, 808-815.	1.2	112
62	Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv006-djv006.	6.3	112
63	Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. <i>Breast Cancer Research</i> , 2016, 18, 1.	5.0	110
64	Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. <i>Breast Cancer Research and Treatment</i> , 1998, 48, 53-64.	2.5	107
65	Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2010, 28, 5147-5152.	1.6	106
66	Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer. <i>Oncologist</i> , 2010, 15, 457-465.	3.7	104
67	Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptorâ€”Positive Breast Cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013, 13, 421-432.e8.	2.4	104
68	Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. <i>Breast Cancer Research and Treatment</i> , 2002, 74, 65-76.	2.5	98
69	Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. <i>Journal of Clinical Oncology</i> , 2004, 22, 4184-4192.	1.6	98
70	Is tamoxifen effective in prevention of breast cancer?. <i>Lancet</i> , The, 1998, 352, 80-81.	18.7	95
71	Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. <i>Clinical Therapeutics</i> , 2007, 29, 230-241.	2.5	94
72	Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 3066-3071.	1.6	90

#	ARTICLE	IF	CITATIONS
73	The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 86-96.	1.6	90
74	Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. <i>Annals of Oncology</i> , 2014, 25, 992-998.	1.2	90
75	Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 295-300.	2.5	89
76	Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013, 105, 654-663.	6.3	88
77	Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1041-1048.	1.6	87
78	Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival. <i>Journal of Clinical Oncology</i> , 2003, 21, 2500-2507.	1.6	84
79	Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 295-310.	2.5	83
80	Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. <i>Journal of Clinical Oncology</i> , 2011, 29, 3869-3876.	1.6	83
81	Prospective Study of 2-[¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 1274-1279.	1.6	83
82	Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response. <i>Journal of Clinical Oncology</i> , 2010, 28, 723-730.	1.6	82
83	American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. <i>Journal of Clinical Oncology</i> , 2003, 21, 2597-2599.	1.6	81
84	HER2/neu in systemic therapy for women with breast cancer: a systematic review. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 209-229.	2.5	81
85	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. <i>Cancer</i> , 2013, 119, 1908-1915.	4.1	81
86	The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 1097-1105.	2.2	81
87	Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2008, 34, 157-174.	7.7	80
88	An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1997, 44, 201-210.	2.5	79
89	Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1994, 31, 83-94.	2.5	77
90	High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 517-525.	2.5	77

#	ARTICLE	IF	CITATIONS
91	Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil. <i>New England Journal of Medicine</i> , 1993, 328, 1081-1084.	27.0	76
92	Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2005, 23, 6037-6042.	1.6	76
93	Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2008, 34, 539-557.	7.7	73
94	Bone-Targeted Agents and Skeletal-Related Events in Breast Cancer Patients with Bone Metastases: The State of the Art. <i>Current Oncology</i> , 2012, 19, 259-268.	2.2	73
95	Body radiation exposure in breast cancer radiotherapy: Impact of breast IMRT and virtual wedge compensation techniques. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 52-58.	0.8	68
96	Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. <i>Journal of Clinical Oncology</i> , 2016, 34, 1065-1071.	1.6	65
97	Biological Significance of Occult Micrometastases in Histologically Negative Axillary Lymph Nodes in Breast Cancer Patients Using the Recent American Joint Committee on Cancer Breast Cancer Staging System. <i>Breast Journal</i> , 2006, 12, 294-301.	1.0	63
98	Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 135-144.	2.5	62
99	Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. <i>Journal of Clinical Oncology</i> , 2004, 22, 269-276.	1.6	59
100	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2020, 38, 1875-1886.	1.6	59
101	Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. <i>Journal of Clinical Oncology</i> , 2011, 29, 3605-3610.	1.6	57
102	A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. <i>Breast Cancer Research and Treatment</i> , 1997, 44, 211-215.	2.5	55
103	Predicting Anthracycline Benefit: <i>TOP2A</i> and <i>CEP17</i> Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015, 33, 1680-1687.	1.6	55
104	The efficacy of bone scanning in the follow-up of patients with operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 1984, 4, 303-307.	2.5	54
105	Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. <i>Journal of Clinical Oncology</i> , 2008, 26, 37-43.	1.6	53
106	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. <i>European Journal of Cancer</i> , 2013, 49, 2621-2632.	2.8	53
107	Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 439-448.	2.5	50
108	A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound. <i>Scientific Reports</i> , 2017, 7, 45733.	3.3	49

#	ARTICLE	IF	CITATIONS
109	First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study. <i>Oncology</i> , 2012, 82, 218-227.	1.9	47
110	Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. <i>Cancer Research</i> , 2016, 76, 7012-7023.	0.9	47
111	Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 407-420.	2.5	47
112	Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 474-482.	10.7	45
113	Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities. <i>Scientific Reports</i> , 2017, 7, 10352.	3.3	44
114	Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 153-162.	2.5	43
115	Prognostic factors affecting the natural history of node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 89, 35-45.	2.5	42
116	Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?. <i>Clinical Breast Cancer</i> , 2020, 20, e54-e64.	2.4	41
117	Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. <i>Cancer Treatment Reviews</i> , 1996, 22, 91-96.	7.7	40
118	Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach. <i>Oncotarget</i> , 2016, 7, 45094-45111.	1.8	38
119	Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 4458-4465.	1.6	37
120	Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?. <i>Breast Cancer Research and Treatment</i> , 2009, 114, 387-389.	2.5	37
121	Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 265-271.	1.6	36
122	A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canadaâ€”Clinical Trials Group Trial,) Tj ETQq0 0 0 rgB2/Overlock 10 Tf 50		
123	Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues. <i>Clinical Cancer Research</i> , 2006, 12, 1056s-1060s.	7.0	33
124	Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1386.	4.1	33
125	Adjuvant targeted therapy in early breast cancer. <i>Cancer</i> , 2009, 115, 1154-1168.	4.1	32
126	Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle. <i>Journal of Clinical Oncology</i> , 2010, 28, 3405-3407.	1.6	32

#	ARTICLE	IF	CITATIONS
127	Combining endocrine agents with chemotherapy: Which patients and what sequence?. <i>Cancer</i> , 2008, 112, 718-722.	4.1	31
128	Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. <i>Breast Cancer Research</i> , 2014, 16, R8.	5.0	31
129	Adjuvant Therapy for Premenopausal Women With Breast Cancer: Is It Time for Another Paradigm Shift?. <i>Journal of Clinical Oncology</i> , 2002, 20, 4611-4614.	1.6	29
130	Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1077-1085.	10.7	29
131	A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 1992, 22, 263-272.	2.5	28
132	Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ?. <i>Breast Cancer Research and Treatment</i> , 2004, 87, 265-272.	2.5	28
133	The Use of Endocrine Therapy. <i>Hematology/Oncology Clinics of North America</i> , 1989, 3, 765-805.	2.2	27
134	Menopausal estrogen replacement therapy in women with breast cancer. <i>Cancer</i> , 1995, 75, 1-3.	4.1	27
135	Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases. <i>Scientific Reports</i> , 2018, 8, 9013.	3.3	27
136	The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 6.	5.2	26
137	Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer. , 1997, 6, 178-189.		24
138	Current and future directions in medical therapy for breast carcinoma. <i>Cancer</i> , 2000, 88, 3065-3072.	4.1	24
139	Health-related quality of life and disease symptoms in postmenopausal women with HR ⁺ , HER2 ⁻ advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013, 29, 1463-1473.	1.9	24
140	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTO Phase III Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw037.	6.3	24
141	Cardiovascular Health and Aromatase Inhibitors. <i>Drugs</i> , 2006, 66, 1727-1740.	10.9	23
142	Adjuvant therapy of the very young woman. <i>Breast</i> , 2007, 16, 136-146.	2.2	22
143	Aromatase Inhibitors in Adjuvant Therapy of Breast Cancer: Before, Instead of, or Beyond Tamoxifen. <i>Journal of Clinical Oncology</i> , 2005, 23, 4850-4852.	1.6	21
144	Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?. <i>Journal of Clinical Oncology</i> , 2001, 19, 3795-3797.	1.6	20

#	ARTICLE	IF	CITATIONS
145	Hormone Replacement in Women with a History of Breast Cancer. <i>Oncologist</i> , 2001, 6, 353-362.	3.7	20
146	Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2009, 27, 3875-3876.	1.6	20
147	Activity of fulvestrant in HER2-overexpressing advanced breast cancer. <i>Annals of Oncology</i> , 2010, 21, 1246-1253.	1.2	20
148	A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. <i>European Journal of Cancer</i> , 1993, 29, 37-43.	2.8	19
149	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 150, 605-611.	2.5	19
150	Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. <i>Oncologist</i> , 2018, 23, 768-775.	3.7	19
151	Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. <i>Journal of Clinical Oncology</i> , 2018, 36, 563-571.	1.6	19
152	Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women. <i>Breast Cancer Research</i> , 2005, 7, 70-6.	5.0	18
153	Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010, 119, 347-356.	2.5	18
154	Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2018, 91, 38-46.	2.8	17
155	Ascertaining Prognosis for Breast Cancer in Node-Negative Patients with Innovative Survival Analysis. <i>Breast Journal</i> , 2006, 12, 37-47.	1.0	16
156	Selective Application of Axillary Node Dissection in Elderly Women with Early Breast Cancer. <i>Annals of Surgical Oncology</i> , 2007, 14, 652-659.	1.5	16
157	Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, 54-62.	7.7	16
158	Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 217-227.	2.5	16
159	<i>A priori</i> prediction of breast tumour response to chemotherapy using quantitative ultrasound imaging and artificial neural networks. <i>Oncotarget</i> , 2019, 10, 3910-3923.	1.8	16
160	Systemic Adjuvant Therapy for Node-Negative Breast Cancer: Proven or Premature?. <i>Annals of Internal Medicine</i> , 1989, 111, 1.	3.9	15
161	The best use of adjuvant endocrine treatments. <i>Breast</i> , 2003, 12, 497-508.	2.2	15
162	The impact of a breast cancer diagnosis in young women on their relationship with their mothers. <i>Breast</i> , 2014, 23, 50-55.	2.2	15

#	ARTICLE	IF	CITATIONS
163	Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology, 2012, 30, 559-559.	1.6	15
164	Review of the Clinical Studies Using the 21-Gene Assay. Oncologist, 2010, 15, 447-456.	3.7	14
165	Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer. Oncologist, 2017, 22, 12-24.	3.7	14
166	The standardization of estrogen receptors. Journal of Steroid Biochemistry and Molecular Biology, 1993, 45, 367-373.	2.5	13
167	The Henrietta Banting Breast Centre database: A model for clinical research utilizing a hospital-based inception cohort. Journal of Clinical Epidemiology, 1995, 48, 779-786.	5.0	13
168	Competing risks of death in younger and older postmenopausal breast cancer patients. World Journal of Clinical Oncology, 2014, 5, 1088.	2.3	13
169	Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clinical Breast Cancer, 2018, 18, 78-87.	2.4	13
170	neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II. Journal of Clinical Oncology, 2003, 21, 399-400.	1.6	12
171	Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. Breast, 2007, 16, 1-9.	2.2	11
172	Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27. Cancer, 2017, 123, 2444-2451.	4.1	11
173	Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). European Journal of Cancer, 2021, 148, 287-296.	2.8	11
174	Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?. Journal of Clinical Oncology, 2011, 29, 1651-1652.	1.6	10
175	A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer, 2001, 92, 23-29.	4.1	9
176	The fox guarding the clinical trial: internal vs. external validity in randomized studies. , 1999, 8, 275-275.		8
177	Optimal Chemotherapy for Women With Breast Cancer: The Plot Thickens. Journal of Clinical Oncology, 2003, 21, 963-964.	1.6	8
178	Endocrine symptoms to predict risk of recurrence?. Lancet Oncology, The, 2008, 9, 1117-1119.	10.7	8
179	A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22. SpringerPlus, 2015, 4, 631.	1.2	8
180	Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. Cmaj, 2002, 166, 1017-22.	2.0	8

#	ARTICLE	IF	CITATIONS
181	Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?. <i>European Journal of Cancer</i> , 2017, 70, 143-145.	2.8	7
182	Breast Cancer Screening: Beyond Mortality. <i>Journal of Breast Imaging</i> , 2019, 1, 161-165.	1.3	7
183	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. <i>Npj Breast Cancer</i> , 2020, 6, 22.	5.2	7
184	The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1132-1137.	1.0	7
185	Tamoxifen and Hypercalcemia. <i>Annals of Internal Medicine</i> , 1978, 89, 423.	3.9	6
186	Tamoxifen and Metastatic Breast Cancer. <i>Annals of Internal Medicine</i> , 1978, 89, 721.	3.9	5
187	Should Tamoxifen Be Used to Treat Premenopausal Women with Breast Cancer?. <i>Cancer Investigation</i> , 2000, 18, 685-686.	1.3	5
188	Adjuvant endocrine therapies for pre-/perimenopausal women. <i>Breast</i> , 2005, 14, 547-554.	2.2	5
189	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 561-561.	1.6	5
190	Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?. <i>Oncologist</i> , 2009, 14, 959-962.	3.7	4
191	Octreotide LAR and tamoxifen versus tamoxifen in phase III randomized early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 353-360.	2.5	4
192	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. <i>European Journal of Cancer</i> , 2016, 56, 85-92.	2.8	4
193	A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 555-555.	1.6	4
194	Clinical management and resolution of stomatitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 558-558.	1.6	4
195	Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 41, 53-60.	2.3	3
196	High levels of uPA and PAI-1 predict a good response to anthracyclines. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 625-626.	2.5	3
197	An update on adjuvant systemic therapy for elderly patients with early breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1881-1888.	1.8	3
198	Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer. <i>Psycho-Oncology</i> , 1997, 6, 178-189.	2.3	3

#	ARTICLE	IF	CITATIONS
199	Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC).. Journal of Clinical Oncology, 2013, 31, 1033-1033.	1.6	3
200	Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario.. Journal of Clinical Oncology, 2014, 32, 583-583.	1.6	3
201	Is exercise effective in reducing the risk of breast cancer in postmenopausal women?. Cmaj, 2004, 170, 787-787.	2.0	2
202	A review of exemestane in the management of breast cancer. Expert Opinion on Pharmacotherapy, 2005, 6, 2353-2363.	1.8	2
203	Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life. European Journal of Cancer, 2007, 43, 1644-1645.	2.8	2
204	Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence. European Journal of Cancer, 2016, 68, 176-178.	2.8	2
205	Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology, 2013, 31, 553-553.	1.6	2
206	Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney studyâ€”NCT00811369.. Journal of Clinical Oncology, 2013, 31, 574-574.	1.6	2
207	The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Breast, 2021, 60, 295-301.	2.2	2
208	Tailored targeted therapy for all: a realistic and worthwhile objective against. Breast Cancer Research, 2009, 11, S8.	5.0	1
209	Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?. Breast Cancer Research and Treatment, 2011, 127, 587-588.	2.5	1
210	The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?. European Journal of Cancer, 2016, 68, 173-175.	2.8	1
211	An update on treatment for post-menopausal metastatic breast cancer in elderly patients. Expert Opinion on Pharmacotherapy, 2018, 19, 597-609.	1.8	1
212	Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. Cancer Treatment and Research, 2009, 147, 1-29.	0.5	1
213	Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?. Breast Cancer Research, 2008, 10, S23.	5.0	0
214	Reply to P. Ameri et al. Journal of Clinical Oncology, 2012, 30, 1396-1396.	1.6	0
215	P2â€³34: Cognitive Sequelae of Adjuvant Endocrine therapy for the Treatment of Breast Cancer in Older Women: A Feasibility Study. Alzheimer's and Dementia, 2016, 12, P770.	0.8	0
216	Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Breast Cancer Research and Treatment, 2016, 157, 101-108.	2.5	0

#	ARTICLE	IF	CITATIONS
217	Extended adjuvant therapy: the role of subset analyses. <i>Lancet Oncology</i> , The, 2017, 18, 1431-1433.	10.7	0
218	Identifying research priorities in the treatment of patients with early breast cancer: from the patient perspective. <i>Breast</i> , 2019, 48, S21-S22.	2.2	0
219	Guidelines, Consensus Conferences and Overviews (Meta-analysis). <i>Cancer Treatment and Research</i> , 2009, 151, 63-76.	0.5	0
220	Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 557-557.	1.6	0
221	The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1550-1550.	1.6	0